189 Avsnitt

  1. Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC

    Publicerades: 2025-03-25

  2. Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer

    Publicerades: 2025-02-20

  3. Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

    Publicerades: 2025-02-10

  4. Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer

    Publicerades: 2025-01-09

  5. Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

    Publicerades: 2024-10-22

  6. Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations

    Publicerades: 2024-10-16

  7. ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

    Publicerades: 2024-10-01

  8. A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

    Publicerades: 2024-09-30

  9. Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

    Publicerades: 2024-09-06

  10. Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

    Publicerades: 2024-09-05

  11. ROS1-Alterations and Molecular Testing in Advanced NSCLC

    Publicerades: 2024-08-28

  12. Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

    Publicerades: 2024-08-05

  13. Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

    Publicerades: 2024-07-22

  14. Current Clinical Practice and NCCN Guidelines for CLL/SLL

    Publicerades: 2024-07-18

  15. Congress to Clinic: Expert Takeaways on Emerging Data for MPNs

    Publicerades: 2024-07-12

  16. CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways

    Publicerades: 2024-07-11

  17. Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

    Publicerades: 2024-07-09

  18. Congress to Clinic: Expert Takeaways on Emerging Data for AML

    Publicerades: 2024-07-08

  19. Congress to Clinic: Expert Takeaways on Emerging Data for MDS

    Publicerades: 2024-07-05

  20. Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer

    Publicerades: 2024-05-14

1 / 10

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

Visit the podcast's native language site